Meropenem
- Generic Name
- Meropenem
- Brand Names
- Vabomere
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O5S
- CAS Number
- 96036-03-2
- Unique Ingredient Identifier
- YOP6PX0BAO
- Background
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
...
- Indication
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, vi...
- Associated Conditions
- Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Meningitis, Bacterial, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin infection bacterial
- Associated Therapies
- -
AbioKin - Antibiotic Kinetics
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2021-01-19
- Target Recruit Count
- 1500
- Registration Number
- NCT02609646
- Locations
- 🇮🇹
Ospedale S. Giovanni di Dio ASL 10, Servizio Anestesia e Rianimazione, Firenze, FI, Italy
🇮🇹Ospedale San Giovanni di Dio, Orbetello, Grosseto, Italy
🇮🇹Ospedale A. Manzoni, U.O. Anestesia e Rianimazione 1, Lecco, Lombardia, Italy
Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT02506686
A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
- Conditions
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 609
- Registration Number
- NCT02486627
Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 83
- Registration Number
- NCT02475733
- Locations
- 🇺🇸
CHOC Children's, Orange, California, United States
🇨🇿Oblastni Nemocnice Kolin, a.s., Nemocnice Stredoceskeho Kraje, Detske oddeleni, Kolin III, Czechia
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 110
- Registration Number
- NCT02463747
- Locations
- 🇮🇱
Tel-Aviv Sourasky Medicak center / BMT Unit, Tel-Aviv, Israel
Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response
- Conditions
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 100
- Registration Number
- NCT02437045
- Locations
- 🇦🇺
John Hunter Hospital, New Lambton, New South Wales, Australia
🇸🇬National University Hospital Singapore, Singapore, Singapore
🇦🇺Wollongong Hospital, Wollongong, New South Wales, Australia
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 46
- Registration Number
- NCT02349841
- Locations
- 🇿🇦
TASK Foundation NPC, Cape Town, Western Cape, South Africa
Bioequivalence of Two Formulations of Meropenem Intravenous Injection
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02344563
Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units
- Conditions
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Sutep Jaruratanasirikul
- Target Recruit Count
- 9
- Registration Number
- NCT02213796
- Locations
- 🇹🇭
Prince of Songkla University, Hat Yai, Songkhla, Thailand
Comparing the Outcome in Patients of Acute Pancreatitis, With and Without Prophylactic Antibiotics
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Benazir Bhutto Hospital, Rawalpindi
- Target Recruit Count
- 90
- Registration Number
- NCT02212392
- Locations
- 🇵🇰
Benazir Bhutto Hospital, Rawalpindi, Punjab, Pakistan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.